A multi-center comparative study of Atezolizumab plus Bevacivumab and Lenvatinib as primary systemic therapy for un-resectable hepatocellular carcinoma (HCC): focus on thrombotic and hemorrhagic adverse events

被引：0

作者：

Tizzani, M. ^{[1
,2
]}

Mazzarelli, C. ^{[3
]}

Burlone, M. ^{[4
]}

Carucci, P. ^{[1
]}

Caviglia, G. P. ^{[5
]}

Lisi, C. ^{[1
,2
]}

Canalis, C. ^{[1
,2
]}

Cesarini, L. ^{[3
]}

Pirisi, M. ^{[6
]}

Acquaviva, A. ^{[7
]}

Rolle, E. ^{[1
]}

Pochettino, P. ^{[8
]}

Bencardino, K. ^{[9
]}

Villa, F. ^{[9
]}

Angiolillo, M. ^{[2
,10
]}

Scaldaferri, M. ^{[10
]}

Castellana, E. ^{[10
]}

Cattel, F. ^{[10
]}

Airoldi, M. ^{[8
]}

Saracco, G. M. ^{[1
,2
]}

Gaia, S. ^{[1
]}

机构：

[1] AOU Citta Salute & Sci, Div Gastroenterol & Hepatol, Turin, Italy

[2] Univ Turin, Turin, Italy

[3] Hepatol & Gastroenterol ASST GOM Niguarda, Milan, Italy

[4] AOU Maggiore Carita Novara, Med Interna 1, Novara, Italy

[5] Univ Turin, Dept Med Sci, Turin, Italy

[6] Univ Piemonte Orientale, Dipartimento Med Traslaz, Vercelli, Italy

[7] Osped S Andrea Vercelli, Med Interna, Vercelli, Italy

[8] AOU Citta Salute & Sci, Div Med Oncol 2, Turin, Italy

[9] Oncol ASST GOM Niguarda, Milan, Italy

[10] Citta Salute & Sci, Div Hosp Pharm, Turin, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷

关键词：

D O I：

10.1016/j.dld.2024.01.146

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

F-41

引用

页码：S84 / S84

页数：1

共 5 条

[1] A multi-center comparison of Atezolizumab plus Bevacizumab and Lenvatinib as primary systemic therapy for unresectable hepatocellar carcinoma: focus on thrombotic and hemorragic adverse events
Tizzani, Marco
Mazzarelli, Chiara
Burlone, Michela Emma
Carucci, Patrizia
Caviglia, Gian Paolo
Lisi, Chiara
Canalis, Chiara
Cesarini, Lucia
Pirisi, Mario
Acquaviva, Antonio
Rolle, Emanuela
Pochettino, Paolo
Bencardino, Katia
Villa, Federica
Angiolillo, Martina
Castellana, Eleonora
Scaldaferri, Matilde
Cattel, Francesco
Airoldi, Mario
Saracco, Giorgio Maria
Gaia, Silvia
JOURNAL OF HEPATOLOGY, 2024, 80 : S451 - S451
[2] Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
Kim, Beom Kyung
Cheon, Jaekyung
Kim, Hyeyeong
Kang, Beodeul
Ha, Yeonjung
Kim, Do Young
Hwang, Seong Gyu
Chon, Young Eun
Chon, Hong Jae
CANCERS, 2022, 14 (07)
[3] Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Song, D.
Zheng, L.
Zhang, A.
Cao, F.
Hao, W.
Zhao, Z.
Zheng, J.
Lu, D.
ANNALS OF ONCOLOGY, 2023, 34 : S615 - S615
[4] Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Lee, C-K.
Yoo, C.
Park, S. J.
Kim, H.
Korphaisarn, K.
Kim, J. W.
Chen, S-C.
Kim, I.
Kim, M.
Chan, S. L.
Kim, J. W.
Tai, D. W. M.
Oh, S. B.
Chen, C-T.
Bae, W. K.
Kim, H.
Hong, J. Y.
Choi, H. J.
Chon, H. J.
Lee, M. A.
ANNALS OF ONCOLOGY, 2023, 34 : S603 - S603
[5] Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study
Chon, H.
Heo, J.
Evans, T. R. J.
Kim, D. Y.
Lim, H. Y.
Macarulla Mercade, T.
Gomez Martin, C.
Moreno Garcia, V.
Ryu, M. H.
Baumann, P.
Bhoi, S.
Jensen, M.
Tunblad, K.
Wallberg, H.
Oberg, F. G.
Reig Monzon, M. E.
ANNALS OF ONCOLOGY, 2024, 35 : S672 - S673

← 1 →